Advancing Parkinson's Disease Research: Standardized Human Cell Models and Therapeutic Insights
A new human stem cell platform funded by The Michael J. Fox Foundation for Parkinson's Research aims to address the lack of standardized human cell model systems for studying Parkinson's disease and supporting therapeutic research. The Jackson Laboratory (JAX) has received a $1.8 million grant to collaborate with the New York Stem Cell Foundation (NYSCF) in advancing human disease modeling and accelerating biomedical discovery.
The project focuses on the GBA1 gene, a common genetic risk factor for Parkinson's disease that affects the cell's recycling system. Researchers aim to understand how changes in GBA1 disrupt cell function and contribute to the disease. By creating standardized human brain cell models carrying GBA1 variants, the team will develop methods to study the gene's function in cells, particularly in microglia and neurons relevant to Parkinson's disease progression.
The goal of the JAX-NYSCF Collaborative is to provide researchers and industry partners with accessible human cell modeling systems that link genetic changes to cellular processes. By utilizing induced pluripotent stem cells and advanced assays, the researchers will identify disrupted GBA1 function and its impact on the cell's recycling system. The resulting research methods, modeling systems, and open datasets will aid in uncovering mechanisms underlying Parkinson's disease and evaluating potential therapies more effectively.
In conclusion, the collaboration between JAX and NYSCF, supported by The Michael J. Fox Foundation, aims to standardize human cell modeling systems for Parkinson's disease research. By focusing on the GBA1 gene and its effects on cell function, the project seeks to provide valuable insights into disease mechanisms and therapeutic approaches.